Funded Tech Companies

Sirtris Pharmaceuticals

Operating out of Cambridge, Sirtris Pharmaceuticals was acquired by GlaxoSmithKline plc.

Company Overview

Contact Information

Company Background Information

Overview

Sirtris Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins, a recently discovered family of enzymes that promotes the body's natural defense against disease. Also known as class III histone deacetylases (HDACs), sirtuins are attractive drug targets for diseases of aging, including metabolic and neurological diseases.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

4/22/2008

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Christoph Westphal

        

Chief Operating Officer

Garen Bohlin

        

Vice President

Peter Elliott

        

VP - Finance

Paul Brannelly

        

VP - R & D

Michael Jirousek

        

Company Investors

• Cargill Ventures
• Genzyme Ventures
• Polaris Partners
• Three Arch Partners
• QVT Fund
• Novartis BioVenture Fund
• Polaris Partners (Alan Crane)
• Skyline Ventures (John Freund)
• Cardinal Partners (John Clarke)
• Covera Ventures
• TVM Capital (Stephen Hoffman)

Browse more funded tech companies:

Sirrus | SIRUM

Share this article

About Our Venture Capital Database

This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary